VALNEVA (EPA:VLA) | WebDisclosure

Basculer en Français

10367	Companies
215877	Keywords
145600	Articles
114307	Press releases

Home
Companies
VALNEVA

BRIEF

published on 05/06/2026 at 11:41, 1 day 5 hours ago

Valneva announces the publication of its financial results for the first quarter of 2026

Financial Results Web Conference Clinical Development Valneva Vaccines
BRIEF

published on 05/06/2026 at 11:41, 1 day 5 hours ago

Valneva annonce la publication de ses résultats financiers du premier trimestre 2026

Résultats Financiers Développement Clinique Valneva Vaccins Webconférence
PRESS RELEASE

published on 05/06/2026 at 11:36, 1 day 5 hours ago

Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026
Valneva SE to report First Quarter 2026 Consolidated Financial Results on May 13, 2026. Live webcast available for discussion and business update

Financial Results Business Update Valneva SE Live Webcast Vaccine Company
PRESS RELEASE

published on 05/06/2026 at 11:36, 1 day 5 hours ago

Valneva publiera ses résultats financiers consolidés du premier trimestre le 13 mai 2026
Valneva SE publiera ses résultats financiers du premier trimestre le 13 mai 2026. La webconférence en direct commentera les résultats et l'activité de la société

Résultats Financiers Développement Valneva SE Vaccins Webconférence
BRIEF

published on 03/31/2026 at 14:30, 1 month 7 days ago

Le vaccin contre la maladie de Lyme de Valneva est prometteur malgré le non-respect du critère d'évaluation principal.

Objectif De Cours Valneva SE Approbation De La FDA Essai De Phase 3 Vaccin Contre La Maladie De Lyme
BRIEF

published on 03/31/2026 at 14:30, 1 month 7 days ago

Valneva's Lyme Disease Vaccine Shows Promise Despite Missed Trial Endpoint

FDA Approval Price Target Phase 3 Trial Valneva SE Lyme Disease Vaccine
PRESS RELEASE

published on 03/31/2026 at 14:25, 1 month 7 days ago

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates Valneva SE (FR0004056851) analysis post Lyme phase 3 trial topline results with Pfizer. Despite missing primary endpoint, optimism remains for FDA approval

FDA Approval First Berlin Equity Research Valneva SE Pfizer Lyme Vaccine
BRIEF

published on 03/26/2026 at 17:50, 1 month 11 days ago

Valneva at the 25th World Vaccine Congress in Washington

Valneva World Vaccine Congress Clinical Studies Vaccination Chikungunya
BRIEF

published on 03/26/2026 at 17:50, 1 month 11 days ago

Valneva au 25ème World Vaccine Congress de Washington

Valneva World Vaccine Congress Études Cliniques Vaccination Chikungunya
PRESS RELEASE

published on 03/26/2026 at 17:45, 1 month 11 days ago

Valneva participera à plusieurs événements lors du 25ème World Vaccine Congress de Washington
Valneva participera au 25ème World Vaccine Congress de Washington avec des présentations sur le vaccin contre le chikungunya. La société rencontrera des partenaires et sera présente dans la zone d'exposition

Valneva World Vaccine Congress Partenaires Vaccin Chikungunya

Accesswire

Published on 05/07/2026 at 16:35, 24 minutes ago

Caledonia Mining Corporation Plc New Corporate Video
Published on 05/07/2026 at 15:15, 1 hour 44 minutes ago

ACCESS Newswire Launches ACCESS Insights & Analytics, AI-Powered Press Release Scoring Platform
Published on 05/07/2026 at 14:35, 2 hours 24 minutes ago

Worksport (NASDAQ: WKSP) Announces Q1 2026 Earnings Call Date and Launch of Investor Townhall Series
Published on 05/07/2026 at 14:30, 2 hours 29 minutes ago

Rio Grande Resources Announces Results of First Annual General Meeting and Re-Appointments
Published on 05/07/2026 at 14:30, 2 hours 29 minutes ago

Loar Holdings Inc. Reports Q1 2026 Record Results and Upward Revision to 2026 Outlook

View all ACCESSWIRE

EQS Group

Published on 05/07/2026 at 16:25, 33 minutes ago

VARON Reinforces Commitment to Seasonal Respiratory Wellness During Allergy Season Across Europe
Published on 05/07/2026 at 16:25, 33 minutes ago

Medit Establishes Global Orthodontic Business Division, Anchored by Strategic Acquisition of Progressive Orthodontics
Published on 05/07/2026 at 16:15, 44 minutes ago

157th Annual General Meeting at wienerberger: All Resolutions Adopted
Published on 05/07/2026 at 15:55, 1 hour 3 minutes ago

MENARINI GROUP: THOMAS CUENI APPOINTED NEW MEMBER OF THE BOARD
Published on 05/07/2026 at 15:28, 1 hour 31 minutes ago

JOST’s Annual General Meeting approves dividend of EUR 1.50 per share and elects new Supervisory Board member

Les Echos

Published on 05/07/2026 at 15:00, 1 hour 59 minutes ago

Déclaration mensuelle du nombre total de droits de vote et du nombre d’actions composant le capital
Published on 05/07/2026 at 07:43, 9 hours 15 minutes ago

ENGIE - Q1 2026 financial information
Published on 05/07/2026 at 07:43, 9 hours 15 minutes ago

ENGIE - Information Financière 1er trimestre 2026
Published on 05/06/2026 at 18:00, 22 hours 58 minutes ago

Mise à disposition des documents relatifs à l'AG du 4 juin 2026
Published on 05/06/2026 at 18:00, 22 hours 58 minutes ago

Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026

View all LES ECHOS COMFI WIRE